This has been discussed recently in a long-term follow-up study on Checkmate 227, which reported that NSCLC patients with tissue-PD-L1 <1% and treated with nivolumab plus ipilimumab experienced a 5-year overall survival rate of 19% indicating that overall survival outcomes are irrespective of tissue-PD-L1 status (52). This evidence concerns the gene CD274 and non-small cell lung carcinoma.